Artemether-lumefantrine-amodiaquine FDC
Product vision |
|
Dosing |
- Co-formulated tablets of artemether (20 mg) - lumefantrine (120 mg) -amodiaquine (40 mg) as a fixed dose combination. Child friendly dispersible taste-masked formulation available
- 1-6 tablets (5 kg to > 55 kg) twice daily for 3 days
|
Efficacy |
- A multi-centre, multi-national study of triple ACT combinations conducted in Myanmar, India, Laos, Bangladesh and DRC, demonstrated PCR-corrected Day 42 efficacy of triple combination of between 96-100% compared to 36-100% for artemether-lumefantrine alone
|
Key features |
- Demonstrated efficacy against Kelch13 partial resistant strains; fixed-dose combination, child friendly formulation, similar pricing
|
Challenges |
- Development of fixed dose combination, and comparative efficacy study of triple combination vs artemether-lumefantrine and amodiaquine-artesunate
- Need for policy endorsement by WHO, national treatment guidelines
|
Status |
- DeTACT study ongoing for lose combination
- Ph III study of co-formulated drug due to start recruitment Q2 2023
|
Next milestone |
- Last-Patient-Last-Visit for DeTACT Q1 2023
|
MMV Project Director |
|